Breast DCIS: how treatment discussions differ from invasive cancer

A DCIS diagnosis can raise two apparently conflicting questions: why consider surgery for something non-invasive, and why is the plan different from treatment for invasive breast cancer? The distinction concerns where the abnormal cells are. In ductal carcinoma in situ, they remain within the breast ducts, without established invasion into surrounding breast tissue. Reports may also use “non-invasive breast cancer” or “stage 0”. Neither term means that distant spread has been diagnosed.

What the biopsy establishes

A biopsy examines sampled tissue. It can identify DCIS, describe how abnormal the cells look and provide receptor results, but it does not necessarily represent the entire area seen on mammography. The team therefore checks whether the pathology explains the imaging findings, where the sample came from and how extensive the changes appear. Examination of the removed tissue can sometimes identify an invasive component that the earlier sample did not show. A revised diagnosis does not automatically mean the condition progressed while you were waiting.

For another assessment, provide the complete pathology report, the biopsy procedure report and original mammogram files. Include the location of any marker placed during biopsy. A message saying “one centimetre of DCIS” can be ambiguous: it could describe a sampled fragment, one focus or an imaging measurement. The clinician needs to know which meaning applies.

Why the discussion usually centres on local treatment

The National Cancer Institute explanation of DCIS describes the uncertainty about which untreated cases will become invasive. The usual discussion concerns removing the affected area and reducing future breast events. Breast-conserving surgery removes the area with surrounding tissue, followed by a discussion of radiotherapy. A mastectomy may be proposed when the abnormality is extensive or spread across separate areas that make satisfactory conservation difficult.

A more extensive operation is not justified by the frightening sound of the diagnosis alone. Ask the surgeon to show which imaging and tissue findings support the recommendation. If the DCIS has hormone receptors, endocrine treatment may be discussed separately, including its expected benefit and unwanted effects. Chemotherapy is not routine treatment for pure DCIS. If a proposal includes it, clarify whether an invasive component has actually been found.

Why a lymph node procedure may still appear in the plan

Pure DCIS treated with standard breast-conserving surgery usually does not require surgical assessment of underarm nodes. Mastectomy or concern about invasion changes that discussion, because reliable sentinel node mapping may be harder after the breast has been removed. This distinction is set out in the ASBrS axillary management resource guide. A proposed sentinel node biopsy does not itself establish that cancer cells are present in a node.

Comparing the whole pathway

Before comparing two offers, establish whether both hospitals agree on the diagnosis and the extent of DCIS. Then compare the planned operation, the possibility of further surgery if margins are inadequate, radiotherapy, any desired reconstruction and subsequent surveillance. A quotation for the operation alone cannot capture those differences. The written recommendation should distinguish decisions that can be made now from those awaiting final surgical pathology.

If monitoring without surgery is being discussed, it needs a defined selection and monitoring protocol and an explanation of the uncertainty. It is not a substitute to adopt independently because the word “non-invasive” sounds reassuring. Equally, having no symptoms does not determine the treatment: DCIS is frequently detected through imaging rather than a lump.

For an oncology second opinion, a useful central question is: “Which features of the distribution of my DCIS justify this amount of local treatment?” That focuses the consultation on the decision in front of you. Assessment arrangements and the availability of particular treatments in Turkey must be confirmed by the receiving hospital.